Most Read Articles
Dr. Joseph Delano Fule Robles, 06 May 2019

Gilteritinib, a novel inhibitor of the tyrosine kinase FLT3, improves survival outcomes among patients with relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutations vs standard chemotherapy, according to results of the phase III ADMIRAL trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US.

Roshini Claire Anthony, 30 Apr 2019

Patients with advanced small cell lung cancer (SCLC) who experience disease progression despite two or more lines of therapy could benefit from pembrolizumab in the third-line setting, according to results from the phase 1b KEYNOTE-028 and phase II KEYNOTE-158* studies presented at AACR 2019.

SBRT reduces acute toxicities in Asians with early-stage prostate cancer

Christina Lau
28 Nov 2018
Dr Darren Poon

Stereotactic body radiotherapy (SBRT) is associated with significantly lower rates of acute gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional fractionated intensity-modulated radiotherapy (CF-IMRT) in Asian patients with early-stage localized prostate cancer.

These results, from a randomized phase II study (n=64) reported at the European Society for Medical Oncology (ESMO) Asia 2018 Congress, suggest that SBRT (5 fractions) is a safe treatment option for Asians with low- or intermediate-risk localized prostate cancer when compared with CF-IMRT (38 fractions). [Poon DMC, et al, ESMO Asia 2018, abstract 218P]

“Patients in the SBRT group had significantly lower rates of grade ≥1 acute GI toxicities and grade ≥2 acute GU toxicities than those in the CF-IMRT group [35 percent vs 87 percent (p<0.0001) and 3 percent vs 24 percent (p=0.0426), respectively],” reported Dr Darren Poon of the Chinese University of Hong Kong. “No grade ≥3 acute toxicities were reported in either group.”
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 06 May 2019

Gilteritinib, a novel inhibitor of the tyrosine kinase FLT3, improves survival outcomes among patients with relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutations vs standard chemotherapy, according to results of the phase III ADMIRAL trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US.

Roshini Claire Anthony, 30 Apr 2019

Patients with advanced small cell lung cancer (SCLC) who experience disease progression despite two or more lines of therapy could benefit from pembrolizumab in the third-line setting, according to results from the phase 1b KEYNOTE-028 and phase II KEYNOTE-158* studies presented at AACR 2019.